Clinical trial
An Early Exploratory Clinical Study of the Safety, Tolerability, and Preliminary Efficacy of JY231 Injection for the Treatment of Relapsed/Refractory Neurologic Immune Disorders
NCT06797024 is registered in ClinicalTrials.gov with Tongji Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Early Exploratory Clinical Study of the Safety, Tolerability, and Preliminary Efficacy of JY231 Injection for the Treatment of Relapsed/Refractory Neurologic Immune Disorders
- Lead sponsor
- Tongji Hospital
- Phase
- Not applicable
- Overall status
- Recruiting
- Start date
- February 28, 2025
- Completion date
- March 31, 2027
- Enrollment
- 20 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.